PHOTO
- His Excellency Abdulrahman Al Owais, Minister of Health and Prevention, attends session
- His Excellency Dr Sultan Al Jaber: Adoption of advanced technology critical for future readiness of UAE’s healthcare sector
Abu Dhabi-UAE: The UAE’s Ministry of Industry and Advanced Technology (MoIAT) today convened a number of the country’s pharmaceutical and medical industry companies in the fourth session of its ‘Future of Industry Dialogue’ series to discuss ways in which the Ministry can drive the strong growth of the sector in a post-COVID-19 economy.
Led by His Excellency Dr Sultan Al Jaber, Minister of Industry and Advanced Technology, the virtual meeting drew the participation of His Excellency Abdulrahman Al Owais, Minister of Health and Prevention, Jürgen Lauterbach, CFO of Julphar, Basem Al-Barahmeh, General Manager of Globalpharma, Emad Nazih Baloosh, General Manager of Medpharma, Dr Shamsheer Vayalil, Chairman of LIFEPharma, Madhukar Tanna, CEO of Pharmax, Dr Salwa Sami, General Manager of Medysinal, Dr Zuhdi Sawalhi, CEO of Medisal, Helda Alosta, General Manager of Monrol, Dr Firas Razouk, General Manager of Fine Healthcare, Mohammed Hamad Al Badi, CEO of Tawam Medical Instruments Factory, Vivekananda Shenoy, General Manager of MicroSynergy Pharmaceuticals, Ashish Koshy, CEO of G42 Healthcare, and Farhan Malik, General Manager of Pure Health.
His Excellency Dr Al Jaber commended the collective efforts of the public and private sectors in responding to the pandemic, from manufacturing personal protective equipment (PPE) to the distribution and testing of vaccines.
Looking ahead, His Excellency Dr Al Jaber said: “Ensuring the future growth and resilience of the UAE’s healthcare sector in a post-pandemic world will depend on planning ahead, reinforcing critical supply chains and establishing a wider network of global partners."
He added: “There is one crucial enabler that we must weave into the DNA of our healthcare industry: the adoption of advanced technologies. We can and must enhance local production of pharmaceuticals and medical equipment by leveraging artificial intelligence (AI) and Industry 4.0 solutions. Not only will this diversify our economy and increase our local efficiencies, but it will improve our preparedness to scale production when it’s most needed, and this is vital to the industry’s future resilience.”
His Excellency underlined the role that MoIAT will play in working with all relevant stakeholders to develop the industrial ecosystem and accelerate the sector’s growth in the UAE. He reaffirmed the Ministry’s commitment to supporting the industrial sector to enhance in-country value, and boost its competitiveness locally, regionally and globally through creating a relevant and strong regulatory environment.
The high-level ‘Future of Industry Dialogue’ initiative, a series of ongoing high-level virtual meetings, was launched in February 2021 by MoIAT to establish a new collaborative framework to build long-term synergies between government and industry in the UAE. Reflecting the UAE’s commitment to developing the national industrial ecosystem, the initiative focuses on identifying and mitigating sector-specific challenges and implementing innovative regulatory, logistical and financing frameworks to drive sustainable industrial development to pave the way for the country to achieve its aspirations in a post-COVID-19 world.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
